These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 36354040

  • 1. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z.
    Lancet; 2022 Nov 26; 400(10366):1869-1881. PubMed ID: 36354040
    [Abstract] [Full Text] [Related]

  • 2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T.
    Lancet; 2023 Aug 12; 402(10401):529-544. PubMed ID: 37385280
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.
    Lancet; 2018 Nov 17; 392(10160):2180-2193. PubMed ID: 30293770
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
    Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D.
    Lancet; 2023 Aug 05; 402(10400):472-483. PubMed ID: 37369232
    [Abstract] [Full Text] [Related]

  • 5. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.
    Lancet; 2018 Jun 30; 391(10140):2607-2618. PubMed ID: 29945727
    [Abstract] [Full Text] [Related]

  • 6. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z.
    Lancet Diabetes Endocrinol; 2022 Jun 30; 10(6):418-429. PubMed ID: 35468322
    [Abstract] [Full Text] [Related]

  • 7. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z.
    Lancet Diabetes Endocrinol; 2018 May 30; 6(5):370-381. PubMed ID: 29483060
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y.
    Lancet Diabetes Endocrinol; 2022 Sep 30; 10(9):623-633. PubMed ID: 35914543
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT.
    Lancet; 2021 Jul 10; 398(10295):143-155. PubMed ID: 34186022
    [Abstract] [Full Text] [Related]

  • 10. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM, SURMOUNT-2 investigators.
    Lancet; 2023 Aug 19; 402(10402):613-626. PubMed ID: 37385275
    [Abstract] [Full Text] [Related]

  • 11. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A.
    Mol Metab; 2018 Dec 19; 18():3-14. PubMed ID: 30473097
    [Abstract] [Full Text] [Related]

  • 12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
    Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW.
    Lancet; 2021 May 08; 397(10286):1736-1748. PubMed ID: 33894838
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC.
    Lancet Diabetes Endocrinol; 2017 Apr 08; 5(4):251-260. PubMed ID: 28110911
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May 08; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 15. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
    Doggrell SA.
    Expert Opin Investig Drugs; 2023 May 08; 32(5):355-359. PubMed ID: 37086147
    [Abstract] [Full Text] [Related]

  • 16. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á.
    Lancet; 2021 Aug 14; 398(10300):583-598. PubMed ID: 34370970
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
    le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM.
    Lancet Diabetes Endocrinol; 2024 Mar 14; 12(3):162-173. PubMed ID: 38330987
    [Abstract] [Full Text] [Related]

  • 19. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
    Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM.
    Diabetologia; 2024 Mar 14; 67(3):470-482. PubMed ID: 38095657
    [Abstract] [Full Text] [Related]

  • 20. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ, PIONEER 4 investigators.
    Lancet; 2019 Jul 06; 394(10192):39-50. PubMed ID: 31186120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.